Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMAGet Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 6,560,000 shares, a growth of 7.0% from the January 31st total of 6,130,000 shares. Based on an average daily volume of 546,800 shares, the short-interest ratio is currently 12.0 days. Approximately 8.8% of the shares of the stock are sold short.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently made changes to their positions in HUMA. Tower Research Capital LLC TRC grew its position in shares of Humacyte by 261.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after purchasing an additional 6,504 shares during the period. American International Group Inc. purchased a new stake in shares of Humacyte in the second quarter valued at $27,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of Humacyte in the fourth quarter valued at $28,000. Victory Capital Management Inc. purchased a new stake in shares of Humacyte in the fourth quarter valued at $29,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Humacyte in the second quarter valued at $30,000. Hedge funds and other institutional investors own 27.36% of the company’s stock.

Humacyte Stock Performance

Humacyte stock opened at $3.48 on Wednesday. The company has a market capitalization of $360.42 million, a price-to-earnings ratio of -4.00 and a beta of 1.53. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 6.79. Humacyte has a fifty-two week low of $1.96 and a fifty-two week high of $5.60. The stock has a fifty day moving average of $3.36 and a two-hundred day moving average of $3.04.

Analysts Set New Price Targets

Several equities analysts have weighed in on HUMA shares. Piper Sandler dropped their price target on Humacyte from $3.50 to $3.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. HC Wainwright started coverage on Humacyte in a research report on Monday, December 11th. They set a “buy” rating and a $6.00 price target for the company. Finally, Benchmark dropped their price target on Humacyte from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, December 27th.

Check Out Our Latest Stock Analysis on Humacyte

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Featured Articles

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.